Mitre Medical Corp. Clinical Data to be Presented Today at EACTS, Including the Introduction and Demonstration of our New Mitral Valve Sizers.
Silicon Valley, October 18, 2018 – The clinical experience with the first 5 Mitral Touch implants enrolled in the ENRAPT MR Trial will be presented today at the EACTS Conference in Milan, Italy. Prof. Dr. med. Klaus Kallenbach of HaerzZenter Luxembourg will also provide the first formal presentation of the
Mitre Medical Corp. to Present a Beating Heart Option for Functional MR Repair and Will Present 6-Month Results from the ENRAPT-MR Trial at Two Upcoming European Cardiac Surgery Conferences.
Silicon Valley, September 7, 2018 –Mitre Medical has been invited to introduce the Mitral Touch epicardial annuloplasty system that enables a beating heart option for the surgical treatment of mitral regurgitation during the 9 September Innovator’s Day poster session, as part of the PCR London Valves meeting, to be held
AngioConsult strengthens the cooperation with Mitre Medical Corp. with the addition of Andrew Kim to the team.
Speyer/Silicon Valley, 05/08/2018 – AngioConsult announces the strengthening of the cooperation with Mitre Medical Corp. with the addition of Andrew Kim to the team. Andrew is the second representative of AngioConsult supporting the medical device company, which is based in Silicon Valley, California. Benjamin Rieck, Sr Managing Partner of the
Mitre Medical Corp. Strengthens Its Team with New Strategic Advisor Maria Sainz. CEO John MacMahon to Present April 19 at Dublin MedTech Innovators Competition
Silicon Valley, April 17, 2018 – Mitre Medical Corp. announces successful recruitment of experienced cardiac surgery business executive Maria Sainz as a Strategic Advisor. Ms. Sainz brings more than two decades of medical device industry experience most recently as President and CEO of CardioKinetix. Notable among prior senior leadership roles,
Silicon Valley, 03/28/2018 – Mitre Medical Corp. announces completion of the feasibility phase of the Study of the Mitral Touch System for the Reduction of Mitral Valve Regurgitation (the EnraptMR Trial). Treatment with the Mitral Touch implant has demonstrated safety and technical success including durability of MR reduction at 30 days. “Validation
Mitre Medical Corp. announces the initial clinical trial enrollment for beating heart surgical mitral regurgitation (MR) reduction with the Mitral Touch® device.
01/26/2018 –This less invasive procedure offers an alternative approach to mitigate moderate to severe mitral regurgitation. Silicon Valley, 01/26/2018 – Mitre Medical Corp. announces the initial enrollment of patients treated with the Mitral Touch epicardial annuloplasty device. The procedures were performed by cardiac surgeons Kestutis Rucinskas, MD, Ph.D. and Gintaras